The Danish pharmaceutical company Bavarian Nordic is to expand its production of the company's vaccine against mpox, the infectious disease previously known as monkeypox. The company writes in a press release that it has the capacity to produce an additional ten million doses by 2025, in addition to current orders.
The company, which is one of the few with an approved vaccine against mpox, also states that it wants to conduct clinical trials in Africa to obtain approval for using the vaccine on children and young people.
"We are ready to work together with the public health organization Africa CDC and thereby save lives and limit the latest outbreak", says the company's CEO Paul Chaplin in the press release.
